☆ 4.6 Review

Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases

CHINESE MEDICAL JOURNAL (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer

Jarrett J. Failing et al.

Summary: Loss of HLA class 1 expression is a mechanism of tumor immune escape and may contribute to resistance to immunotherapy. Patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors can have discordant responses between brain metastases and extracranial sites of disease. While there is moderate agreement in HLA class 1 expression between primary lung tumor and brain metastasis pairs, HLA expression is incongruent in nearly one quarter of patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Oncology

Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape

Seung Geun Song et al.

Summary: The study evaluated the immune microenvironment characteristics in brain metastases of non-small-cell lung cancer and found that tumors were clustered based on organ involvement and EGFR mutation status. Different immune-related functions and pathways were enriched in primary tumors compared to brain metastases, with upregulated immune-related pathways in EGFR-mutated brain metastases.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Oncology

Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy

Lova Sun et al.

Summary: In patients with metastatic non small-cell lung cancer (mNSCLC), the presence of brain metastases (BM) did not significantly impact survival outcomes with pembrolizumab-based therapy. Both systemic and intracranial objective response rates were similar between patients with and without BM. Factors associated with improved survival on Cox analysis included gender, performance status, histology, and first-line therapy.

CLINICAL LUNG CANCER (2021)

Add to Collection

Correction Oncology

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate O17 and O57: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (vol 39, pg 723, 2021)

Borghaei

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman et al.

Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

Add to Collection

Article Cell Biology

Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis

Zhengbo Song et al.

Summary: Through genomic and tumor immune microenvironment analysis of lung cancer patients with brain oligo-metastasis, we identified genetic features associated with brain metastasis as well as differences in immune environments. EGFR was found to be the most common driver gene. The TCR clonality was higher in BM compared to lung tumor, with lower levels of CD8+ TILs in BM but equivalent PD-L1 expression levels.

CELL DEATH & DISEASE (2021)

Add to Collection

Article Oncology

Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling

Johanna Schaffenrath et al.

Summary: The study characterized transcriptional alterations in endothelial cells of brain tumors, revealing deregulation of genes related to cell proliferation, angiogenesis, and extracellular matrix in GBM and BM vasculature. Dysfunction of genes defining the BBB and deregulated expression of genes in vessel-associated fibroblasts in GBM were also identified. These findings contribute to the development of drug delivery platforms and warrant further investigation into the cellular composition of brain tumor stroma.

NEURO-ONCOLOGY (2021)

Add to Collection

Review Oncology

The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis

Charissa A. C. Jessurun et al.

Summary: A systematic review and meta-analysis of 15 observational studies revealed that the use of steroids in BM patients receiving ICI was associated with significantly worse overall survival and systemic progression-free survival. Further research on the dosage, timing, and duration of steroids is needed to optimize outcomes in these patients.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Oncology

Picturing Breast Cancer Brain Metastasis Development to Unravel Molecular Players and Cellular Crosstalk

Ines Figueira et al.

Summary: Breast cancer brain metastasis is a life-threatening condition with poor survival rates. Through microscopic analysis in a mouse model, potential therapeutic targets have been identified for this disease.

CANCERS (2021)

Add to Collection

Article Oncology

Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma

Tao Jiang et al.

Summary: Characterizing the evolutionary trajectory and immune profiling of brain metastasis revealed high intertumor heterogeneity between BM and primary tumors, suggesting early divergence of BM-competent clones. The immunosuppressive microenvironment in BMs, with lower CD8(+) T cell infiltration and elevated CD4(+)Foxp3(+) T cell infiltration and PD-1 expression, indicates unique biological features that can inform innovative therapeutic strategies.

NPJ PRECISION ONCOLOGY (2021)

Add to Collection

Article Oncology

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

D. Rodriguez-Abreu et al.

Summary: Pembrolizumab plus pemetrexed-platinum continues to demonstrate improved efficacy outcomes compared to placebo plus pemetrexed-platinum, with manageable toxicity, supporting its first-line use in previously untreated metastatic nonsquamous non-small-cell lung cancer patients.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020

Wei Cao et al.

Summary: This study summarized the recent changing profiles of cancer burden worldwide and in China, revealing that breast cancer became the most diagnosed cancer globally in 2020. China accounted for 24% of newly diagnosed cases and 30% of cancer-related deaths worldwide in 2020, with a high cancer mortality rate.

CHINESE MEDICAL JOURNAL (2021)

Add to Collection

Article Oncology

Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis

G. Metro et al.

Summary: The study investigated the optimal management for NSCLC patients with PD-L1 >= 50% and asymptomatic BMs treated with pembrolizumab. Different treatment strategies including pembrolizumab alone, whole-brain radiotherapy followed by pembrolizumab, and stereotactic radiosurgery followed by pembrolizumab were compared. Results showed efficacy of pembrolizumab in selected patients, with a need for further prospective studies.

CLINICAL & TRANSLATIONAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases

Tom L. Enright et al.

Summary: The study demonstrated that combining stereotactic radiation (SRT) with immune checkpoint inhibitors (ICIs) can improve overall survival, reduce distant brain failure, and decrease neurologic death in patients with non-small cell lung cancer (NSCLC) brain metastases.

CLINICAL LUNG CANCER (2021)

Add to Collection

Article Oncology

Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases

Benjamin Y. Lu et al.

Summary: This study evaluated the composition and functional properties of tumor-infiltrating lymphocytes within brain metastases and primary lung tumors using multiplexed quantitative immunofluorescence. It found that brain metastases had lower T cell infiltration, markers of cytolytic function, and immune regulatory signals compared to primary lung tumors. However, high TIM-3 and LAG-3 expressions in CD3(+) T-cells were associated with longer survival, highlighting unique aspects of the tumor immune microenvironment within the brain.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Review Oncology

Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors

Regan M. Memmott et al.

Summary: Immune checkpoint inhibitors show promise in treating lung cancer by enhancing immune response, but only a subset of patients respond to this therapy. Research is ongoing to identify biomarkers that can predict the efficacy of these inhibitors in individual patients.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer

Myrto K. Moutafi et al.

Summary: Metastatic lesions tend to have higher PD-L1 expression levels compared to primary lesions, with variation based on histologic subtype, sampling site, and gender. This observation may impact future patient management and trial design.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy

Konstantinos Rounis et al.

Summary: The study identified parameters that may potentially influence the intracranial outcome of patients with advanced NSCLC and brain metastases receiving PD-1/PD-L1 monotherapy, suggesting that age, history of CNS radiotherapy, and primary brain metastatic disease could impact the IC disease control probability. There is a lack of biomarkers for predicting intracranial outcomes in NSCLC patients with BM treated with ICIs, highlighting the need for further research in this area.

CANCERS (2021)

Add to Collection

Review Oncology

Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer

Likui Fang et al.

Summary: The combination therapy of anti-angiogenic agents and immune checkpoint inhibitors has shown promising potential in the management of brain metastases in NSCLC, but faces challenges and issues that need to be addressed.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy

Sally C. M. Lau et al.

Summary: ICIs show remarkable efficacy in the treatment of brain metastases in patients with EGFR/ALK wild-type mNSCLC, providing effective disease control. Baseline radiation plus ICIs can be considered as an effective strategy for patients with PD-L1 50% and further investigation is warranted to delay whole brain radiation therapy in this subgroup of patients.

LUNG CANCER (2021)

Add to Collection

Review Oncology

The blood-tumour barrier in cancer biology and therapy

Patricia S. Steeg

Summary: The blood-brain barrier plays a crucial role in maintaining normal brain function, but modifications in primary brain tumors and brain metastases result in the blood-tumor barrier, further limiting the penetration of therapeutic agents. This challenge highlights the importance of understanding and overcoming the structural and functional complexities of the blood-tumor barrier for improving cancer therapy and patient outcomes.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO

Silvia Scoccianti et al.

Summary: In a multicentric retrospective study from AIRO, the combination of stereotactic radiotherapy (SRT) and immunotherapy (IT) showed better intracranial local progression-free survival in non-small cell lung cancer (NSCLC) patients with brain metastases. Additionally, treating NSCLC patients with IT after extracranial progression at the time of brain metastases diagnosis was associated with improved overall survival.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Biology

Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues

Teresa W. M. Fan et al.

Summary: The study shows that Pembrolizumab can activate innate immune metabolism and functions in primary lung cancer OTC, accompanied by tissue damage, while Pembrolizumab + WGP can inhibit central metabolism in BM-lung cancer OTC, increase pro-inflammatory effector release, and tissue damage. In-depth metabolic and multiplex TME imaging analysis reveals heterogeneous responses to Pembrolizumab in the native TME of primary NSCLC patients, and synergistic effects of Pembrolizumab and WGP in metastatic NSCLC OTC.

ELIFE (2021)

Add to Collection

Article Oncology

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo Negrao et al.

Summary: High TMB and PD-L1 expression are predictive for benefit from ICB treatment in oncogene-driven NSCLCs. NSCLC harboring BRAF mutations demonstrated superior benefit from ICB that may be attributed to higher TMB and higher PD-L1 expression in these tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Epidemiology of brain metastases and leptomeningeal disease

Nayan Lamba et al.

Summary: Brain metastases significantly impact patients with advanced extracranial malignancies, but their incidence remains poorly described. Recent studies have shown the viability of using claims data for epidemiologic investigations of brain metastases.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Oncology

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Hossein Borghaei et al.

Summary: Immunotherapy with nivolumab has shown improved overall survival and safety compared to docetaxel in patients with advanced NSCLC in two phase III trials. Pooled 5-year data demonstrated a significant survival benefit with nivolumab and no new safety concerns.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Clinical Neurology

Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases

Charu Singh et al.

JOURNAL OF NEUROSURGERY (2020)

Add to Collection

Article Oncology

Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study

Guowei Zhang et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

Add to Collection

Article Oncology

Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival

Kolja Pocha et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Characterization of the immune microenvironment in brain metastases from different solid tumors

Jinling Jiang et al.

CANCER MEDICINE (2020)

Add to Collection

Article Oncology

Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy

Alexander F. C. Hulsbergen et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)

Add to Collection

Article Oncology

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Lingzhi Hong et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial

Sarah B. Goldberg et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial

David A. Reardon et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Outcomes to first-line pembrolizumab in patients with PD-L1-high (>= 50%) non-small cell lung cancer and a poor performance status

Joao Alessi et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Oncology

Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases

Jack M. Qian et al.

CANCER (2020)

Add to Collection

Review Oncology

Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic

N. Vilarino et al.

CANCER TREATMENT REVIEWS (2020)

Add to Collection

Article Oncology

Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases

Takehiro Tozuka et al.

THORACIC CANCER (2020)

Add to Collection

Review Clinical Neurology

Management of brain metastases according to molecular subtypes

Riccardo Soffietti et al.

NATURE REVIEWS NEUROLOGY (2020)

Add to Collection

Editorial Material Oncology

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer

Fei Zhou et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Biotechnology & Applied Microbiology

PD-I /PD-LI Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases

Chenglong Sun et al.

ONCOTARGETS AND THERAPY (2020)

Add to Collection

Article Oncology

Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting

Marcus Skribek et al.

CANCERS (2020)

Add to Collection

Article Oncology

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis

Thierry Landre et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

The blood-brain barrier and blood-tumour barrier in brain tumours and metastases

Costas D. Arvanitis et al.

NATURE REVIEWS CANCER (2020)

Add to Collection

Article Chemistry, Analytical

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid

Dick Pluim et al.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2019)

Add to Collection

Article Oncology

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

Lizza E. L. Hendriks et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Article Oncology

Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer

Lucio Crino et al.

LUNG CANCER (2019)

Add to Collection

Article Oncology

PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis

Vanda Teglasi et al.

CLINICAL LUNG CANCER (2019)

Add to Collection

Article Oncology

Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer

Y. Kudo et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors

Ryul Kim et al.

BMC CANCER (2019)

Add to Collection

Article Oncology

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Martin Reck et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Brain metastases

Achal Singh Achrol et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Programmed death ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer

Jie Zhou et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)

Add to Collection

Review Oncology

Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment

Elie El Rassy et al.

CANCER TREATMENT REVIEWS (2018)

Add to Collection

Article Oncology

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer

Louis Fehrenbacher et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

Add to Collection

Article Oncology

Intracerebral efficacy and tolerance of nivolumab in non small-cell lung cancer patients with brain metastases

Clement Gauvain et al.

LUNG CANCER (2018)

Add to Collection

Article Biochemistry & Molecular Biology

A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments

Kevin C. Barry et al.

NATURE MEDICINE (2018)

Add to Collection

Review Oncology

Current state of immunotherapy for glioblastoma

Michael Lim et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking

David Taggart et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)

Add to Collection

Article Multidisciplinary Sciences

Contraction of T cell richness in lung cancer brain metastases

Aaron S. Mansfield et al.

SCIENTIFIC REPORTS (2018)

Add to Collection

Article Oncology

Quantitative Fluorescence Microscopy Measures Vascular Pore Size in Primary and Metastatic Brain Tumors

Rajendar K. Mittapalli et al.

CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases

Kamran A. Ahmed et al.

JOURNAL OF NEURO-ONCOLOGY (2017)

Add to Collection

Article Oncology

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

Narek Shaverdian et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

Sydney R. Gordon et al.

NATURE (2017)

Add to Collection

Article Oncology

Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis

Vanda Teglasi et al.

NEURO-ONCOLOGY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Nadeem Riaz et al.

CELL (2017)

Add to Collection

Review Pathology

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

Shona Hendry et al.

ADVANCES IN ANATOMIC PATHOLOGY (2017)

Add to Collection

Article Oncology

Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma

Christina D. Pham et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection

Article Oncology

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases

Anna S. Berghoff et al.

ONCOIMMUNOLOGY (2016)

Add to Collection

Article Oncology

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

A. S. Mansfield et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Oncology

Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases

Elizabeth Dudnik et al.

LUNG CANCER (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Blood-brain Barrier Remodeling during Brain Metastasis Formation

Jagoda K. Wrobel et al.

MOLECULAR MEDICINE (2016)

Add to Collection

Article Multidisciplinary Sciences

Structural and functional features of central nervous system lymphatic vessels

Antoine Louveau et al.

NATURE (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.